CN101152160A - 含有伊波膦酸盐的口服药物制剂 - Google Patents

含有伊波膦酸盐的口服药物制剂 Download PDF

Info

Publication number
CN101152160A
CN101152160A CNA2007101536726A CN200710153672A CN101152160A CN 101152160 A CN101152160 A CN 101152160A CN A2007101536726 A CNA2007101536726 A CN A2007101536726A CN 200710153672 A CN200710153672 A CN 200710153672A CN 101152160 A CN101152160 A CN 101152160A
Authority
CN
China
Prior art keywords
active substance
form according
coating
dosage form
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101536726A
Other languages
English (en)
Chinese (zh)
Inventor
J·默克尔
R·-D·加贝尔
H·乌格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7791961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101152160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of CN101152160A publication Critical patent/CN101152160A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2007101536726A 1996-04-20 1997-04-21 含有伊波膦酸盐的口服药物制剂 Pending CN101152160A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19615812A DE19615812A1 (de) 1996-04-20 1996-04-20 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19615812.5 1996-04-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 97195629 Division CN1222079A (zh) 1996-04-20 1997-04-21 含有伊波膦酸盐的口服药物制剂

Publications (1)

Publication Number Publication Date
CN101152160A true CN101152160A (zh) 2008-04-02

Family

ID=7791961

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101536726A Pending CN101152160A (zh) 1996-04-20 1997-04-21 含有伊波膦酸盐的口服药物制剂

Country Status (26)

Country Link
US (2) US6143326A (cg-RX-API-DMAC10.html)
EP (2) EP0936913B2 (cg-RX-API-DMAC10.html)
JP (2) JP5037746B2 (cg-RX-API-DMAC10.html)
CN (1) CN101152160A (cg-RX-API-DMAC10.html)
AR (2) AR006652A1 (cg-RX-API-DMAC10.html)
AT (1) ATE404207T1 (cg-RX-API-DMAC10.html)
AU (1) AU722516B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708785A (cg-RX-API-DMAC10.html)
CA (1) CA2251886C (cg-RX-API-DMAC10.html)
CO (1) CO4820394A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ297341B6 (cg-RX-API-DMAC10.html)
DE (2) DE19615812A1 (cg-RX-API-DMAC10.html)
DK (1) DK0936913T4 (cg-RX-API-DMAC10.html)
ES (1) ES2313735T5 (cg-RX-API-DMAC10.html)
HU (1) HU228389B1 (cg-RX-API-DMAC10.html)
IL (2) IL163930A0 (cg-RX-API-DMAC10.html)
NO (1) NO319162B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ332314A (cg-RX-API-DMAC10.html)
PA (1) PA8427301A1 (cg-RX-API-DMAC10.html)
PL (2) PL191363B1 (cg-RX-API-DMAC10.html)
PT (1) PT936913E (cg-RX-API-DMAC10.html)
RU (1) RU2193881C2 (cg-RX-API-DMAC10.html)
SI (1) SI0936913T2 (cg-RX-API-DMAC10.html)
TR (1) TR199802108T2 (cg-RX-API-DMAC10.html)
WO (1) WO1997039755A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA973331B (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
CA2293815C (en) * 1997-06-11 2004-06-29 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
AR024462A1 (es) * 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
HUP0303700A3 (en) * 2000-07-17 2006-07-28 Astellas Pharma Inc Chuo Ku Pharmaceutical composition improved in peroral absorbability
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
JP2002332235A (ja) * 2001-02-01 2002-11-22 Riderway Corp 骨疾患治療用液体医薬組成物
ES2268086T3 (es) * 2001-05-02 2007-03-16 Novartis Ag Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
DE20220902U1 (de) * 2001-12-19 2004-06-09 Astrazeneca Ab Neuer Filmüberzug
EP1455796A1 (en) * 2001-12-21 2004-09-15 The Procter & Gamble Company Method for the treatment of bone disorders
CA2476201C (en) 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
RU2387451C2 (ru) * 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
EP1790347B1 (en) * 2002-12-20 2014-12-24 F. Hoffmann-La Roche AG High dose ibandronate formulation
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) * 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
KR20090037951A (ko) * 2006-07-25 2009-04-16 교와 가부시키가이샤 당의 제제 및 그의 제조 방법
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
WO2009075601A1 (fr) * 2007-12-12 2009-06-18 Alexander Valerievich Melnik Moyen d'indication d'une éventuelle prédisposition de chats à une maladie (variantes) et procédé de détermination de troubles de la santé chez les chats
EP2210596A1 (en) 2009-01-22 2010-07-28 Laboratorios Liconsa, S.A. Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
HUE041795T2 (hu) * 2010-08-31 2019-05-28 Toray Industries Bevonószer szilárd gyógyszerészeti készítményhez, gyógyszerészeti filmkészítmény, és bevonatos szilárd gyógyszerészeti készítmény
KR101799625B1 (ko) * 2011-06-17 2017-11-20 에보니크 룀 게엠베하 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
RU2485957C1 (ru) * 2012-03-16 2013-06-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия последипломного образования" Министерства здравоохранения Российской Федерации (ГБОУ ДПО РМАПО Минздрава России) Средство для лечения низкообменного варианта заболевания скелета у больных с хронической почечной недостаточностью

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE965825C (de) 1949-10-30 1957-06-19 Walter Kloepfer Dipl Ing Dr In Zur Antennenebene senkrecht polarisierter Strahler
US4820698A (en) * 1985-11-04 1989-04-11 The Procter & Gamble Company Antimicrobial agents and process for their manufacture
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5098717A (en) * 1987-12-09 1992-03-24 Thames Pharmacal Co., Inc. Method of treatment for pruritus
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (cg-RX-API-DMAC10.html) * 1992-04-15 1995-01-01 Ciba Geigy
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
CZ287984B6 (cs) * 1993-05-15 2001-03-14 Roche Diagnostics Gmbh Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US5803321A (en) * 1996-11-12 1998-09-08 Randy Hangers, Lll Hanger with ganging element
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery

Also Published As

Publication number Publication date
AR006652A1 (es) 1999-09-08
DK0936913T4 (da) 2012-11-19
SI0936913T2 (sl) 2012-11-30
IL126655A (en) 2004-12-15
US20050089573A1 (en) 2005-04-28
DE19615812A1 (de) 1997-10-23
HUP9903407A3 (en) 2000-11-28
PL329347A1 (en) 1999-03-29
CZ336498A3 (cs) 2000-01-12
TR199802108T2 (xx) 1999-01-18
ES2313735T5 (es) 2012-12-07
HU228389B1 (en) 2013-03-28
AR054350A2 (es) 2007-06-20
CZ297341B6 (cs) 2006-11-15
EP1658852B1 (de) 2016-11-09
ES2313735T3 (es) 2009-03-01
JP5557989B2 (ja) 2014-07-23
JP2000508673A (ja) 2000-07-11
BR9708785A (pt) 1999-08-03
PT936913E (pt) 2008-09-25
AU722516B2 (en) 2000-08-03
PL191910B1 (pl) 2006-07-31
NO319162B1 (no) 2005-06-27
JP5037746B2 (ja) 2012-10-03
CA2251886A1 (en) 1997-10-30
EP0936913B2 (de) 2012-09-19
IL163930A0 (en) 2005-12-18
EP0936913A1 (de) 1999-08-25
EP0936913B1 (de) 2008-08-13
PA8427301A1 (es) 2002-07-30
CO4820394A1 (es) 1999-07-28
NZ332314A (en) 2000-03-27
EP1658852A1 (de) 2006-05-24
DK0936913T3 (da) 2008-10-20
NO984881D0 (no) 1998-10-19
ZA973331B (en) 1998-10-19
IL126655A0 (en) 1999-08-17
HUP9903407A2 (hu) 2000-04-28
US6143326A (en) 2000-11-07
DE59712959D1 (de) 2008-09-25
CA2251886C (en) 2008-06-17
JP2008285500A (ja) 2008-11-27
SI0936913T1 (sl) 2008-12-31
RU2193881C2 (ru) 2002-12-10
NO984881L (no) 1998-10-19
AU2638297A (en) 1997-11-12
ATE404207T1 (de) 2008-08-15
PL191363B1 (pl) 2006-05-31
WO1997039755A1 (de) 1997-10-30

Similar Documents

Publication Publication Date Title
CN101152160A (zh) 含有伊波膦酸盐的口服药物制剂
RU2120798C1 (ru) Твердая фармацевтическая композиция для перорального введения
CA2717456A1 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
CN109310642B (zh) 美沙拉嗪的口服药物组合物
US20070122470A1 (en) New Combination Dosage Form
US20040037884A1 (en) Novel dosage forms of risedronate
WO2006002032A1 (en) Sustained release neutralized divalproex sodium
WO2023281089A2 (en) Pharmaceutical composition comprising naproxen and paracetamol
JP2016539171A (ja) アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物
KR100482931B1 (ko) 이반드로네이트를함유하는경구용약제학적제제
HK1118714A (en) Oral pharmaceutical preparation containing ibandronat
EP4366707A2 (en) Pharmaceutical composition comprising naproxen and paracetamol
CN1222079A (zh) 含有伊波膦酸盐的口服药物制剂
HK1020684A (en) Oral pharmaceutical preparation containing ibandronat
MX2008006727A (en) Oral pharmaceutical dosage form comprising as active ingredients a proton pump inhibitor together with acetyl salicyclic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1118714

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1118714

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080402